Historically, covalent inhibitors were avoided due to toxic side effects, but the latest breakthroughs in targeting have created a new landscape of opportunities. New breakthrough drugs like ibrutinib, sotorasib, and afatinib are reshaping the landscape of covalent inhibitors. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.

‍